Suchergebnisse - "Janetka, James W"

PubPharm (8)

1

Rational design strategies for FimH antagonists : new drugs on the horizon for urinary tract infection and Crohn's disease

enthalten in: Expert opinion on drug discovery | 2017

von Mydock-McGrane, L. | Hannan, T. | Janetka, J.

2

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

enthalten in: Nature | 2017

von Spaulding, C. | Klein, R. | Ruer, S. | +10

CommentIn: Nature. 2017 Jun 22;546(7659):479-480. - PMID 28614303

3

Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections

enthalten in: Journal of medicinal chemistry | 2016

von Mydock-McGrane, L. | Cusumano, Z. | Han, Z. | +10

4

Antivirulence Isoquinolone Mannosides : Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI

enthalten in: ChemMedChem | 2016

von Jarvis, C. | Han, Z. | Kalas, V. | +9

5

Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice

enthalten in: Antimicrobial agents and chemotherapy | 2012

von Guiton, P. | Cusumano, C. | Kline, K. | +6

6

Lead optimization studies on FimH antagonists : discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides

enthalten in: Journal of medicinal chemistry | 2012

von Han, Z. | Pinkner, J. | Ford, B. | +7

7

Treatment and prevention of urinary tract infection with orally active FimH inhibitors

enthalten in: Science translational medicine | 2011

von Cusumano, C. | Pinkner, J. | Han, Z. | +6

CommentIn: Nat Rev Urol. 2012 Jan;9(1):6. - PMID 22200833

8

Structure-based drug design and optimization of mannoside bacterial FimH antagonists

enthalten in: Journal of medicinal chemistry | 2010

von Han, Z. | Pinkner, J. | Ford, B. | +8

1
[1]